TD Cowen Issues Positive Forecast for Versigent (NYSE:VGNT) Stock Price

Versigent (NYSE:VGNT) had its target price lifted by TD Cowen from $58.00 to $59.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen‘s price objective points to a potential upside of 46.44% from the stock’s previous close.

Several other equities analysts have also weighed in on VGNT. Oppenheimer set a $50.00 target price on shares of Versigent in a report on Tuesday, July 21st. The Goldman Sachs Group decreased their price target on shares of Versigent from $59.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, October 6th. Weiss Ratings upgraded Versigent from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Evercore reissued an “outperform” rating and issued a $65.00 price objective on shares of Versigent in a research report on Monday, August 10th. Finally, Zacks Research cut Versigent from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 15th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.08.

Versigent Trading Down 4.0%

VGNT stock traded down $1.68 during midday trading on Thursday, reaching $40.29. 967,057 shares of the company’s stock traded hands, compared to its average volume of 1,522,779. The company has a market capitalization of $2.85 billion and a P/E ratio of 20.98. The company has a debt-to-equity ratio of 7.29, a current ratio of 1.40 and a quick ratio of 1.09. Versigent has a fifty-two week low of $26.34 and a fifty-two week high of $50.88. The business has a 50-day moving average price of $45.08 and a two-hundred day moving average price of $42.71.

Versigent (NYSE:VGNT) last released its quarterly earnings data on Wednesday, November 4th. The company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.12. The business had revenue of $2.45 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Equities research analysts forecast that Versigent will post 7.23 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Kevin Clark sold 47,761 shares of the firm’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $44.36, for a total transaction of $2,118,677.96. Following the completion of the sale, the director directly owned 27,571 shares of the company’s stock, valued at approximately $1,223,049.56. This trade represents a 63.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have sold 220,000 shares of company stock worth $10,065,848.

Institutional Investors Weigh In On Versigent

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Salomon & Ludwin LLC lifted its holdings in Versigent by 78.3% in the 3rd quarter. Salomon & Ludwin LLC now owns 708 shares of the company’s stock worth $32,000 after buying an additional 311 shares in the last quarter. Signaturefd LLC boosted its position in Versigent by 40.0% in the 3rd quarter. Signaturefd LLC now owns 1,121 shares of the company’s stock valued at $50,000 after buying an additional 320 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Versigent by 53.1% during the third quarter. Farther Finance Advisors LLC now owns 1,052 shares of the company’s stock valued at $47,000 after acquiring an additional 365 shares in the last quarter. Fortitude Family Office LLC grew its stake in shares of Versigent by 497.1% during the third quarter. Fortitude Family Office LLC now owns 621 shares of the company’s stock valued at $28,000 after acquiring an additional 517 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Versigent by 54.8% during the third quarter. GAMMA Investing LLC now owns 2,249 shares of the company’s stock valued at $101,000 after acquiring an additional 796 shares in the last quarter.

Key Headlines Impacting Versigent

Here are the key news stories impacting Versigent this week:

• Positive Sentiment: Versigent reported third-quarter revenue of $2.45 billion, up 7.2% year over year, and EPS of $1.91 versus the $1.79 consensus estimate. The revenue figure also exceeded expectations of $2.42 billion. Versigent Reports Third Quarter 2026 Results
• Positive Sentiment: The company declared a quarterly dividend of $0.13 per share, equivalent to $0.52 annually and a yield of about 1.2%. Versigent dividend announcement
• Neutral Sentiment: Royal Bank of Canada and BNP Paribas Exane each maintained an “outperform” rating, while trimming their price targets by $1, to $52 and $54, respectively. The targets still indicate substantial potential upside from the cited $40.29 share price. RBC rating BNP Paribas Exane rating
• Neutral Sentiment: CFO Doug Ostermann is scheduled to participate in a fireside chat at the RBC Capital Markets Global Industrials Conference on November 17; the announcement provides no new financial guidance. Conference announcement
• Negative Sentiment: Despite reported sales growth, Versigent’s adjusted net sales growth was only about 1% year over year, suggesting underlying growth was modest. The small target reductions from both banks may also weigh on sentiment. Quarterly results

Versigent Company Profile

Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.